Commercial utilization of bacteriocins: tackling challenges and exploring their potential as alternatives to antibiotics.

IF 2.5 4区 生物学 Q3 MICROBIOLOGY
Susai Arul Selvan, Vihang Vivek Ghalsasi, Anwesha Bandyopadhyay, Tarun Pal
{"title":"Commercial utilization of bacteriocins: tackling challenges and exploring their potential as alternatives to antibiotics.","authors":"Susai Arul Selvan, Vihang Vivek Ghalsasi, Anwesha Bandyopadhyay, Tarun Pal","doi":"10.1080/17460913.2025.2520693","DOIUrl":null,"url":null,"abstract":"<p><p>The global surge in antibiotic resistance has accelerated the search for alternative antimicrobial strategies, with bacteriocins emerging as promising candidates. These ribosomally synthesized peptides exhibit potent, targeted antimicrobial activity against multidrug-resistant (MDR) pathogens and have shown efficacy in food preservation, pharmaceuticals, and clinical applications. Their specificity and rapid bactericidal action offer distinct advantages over conventional antibiotics, including a potentially lower risk of resistance development. Nonetheless, recent studies report resistance mechanisms such as membrane modifications, efflux pumps, and enzymatic degradation. Despite their potential, only a limited number of bacteriocins have been commercialized primarily for food applications with none yet approved for therapeutic use. Major barriers include low production yields, poor stability, and stringent regulatory challenges. This review presents a comprehensive overview of bacteriocins, including their classification, mechanisms of action, and commercial landscape. It further highlights current innovations aimed at overcoming translational bottlenecks, such as genetic engineering, nanotechnology-based delivery, and fermentation optimization. Ultimately, the review underscores the need for interdisciplinary research and harmonized regulatory frameworks to fully realize bacteriocins' potential in addressing the global antibiotic resistance crisis.</p>","PeriodicalId":12773,"journal":{"name":"Future microbiology","volume":" ","pages":"1-13"},"PeriodicalIF":2.5000,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future microbiology","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1080/17460913.2025.2520693","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The global surge in antibiotic resistance has accelerated the search for alternative antimicrobial strategies, with bacteriocins emerging as promising candidates. These ribosomally synthesized peptides exhibit potent, targeted antimicrobial activity against multidrug-resistant (MDR) pathogens and have shown efficacy in food preservation, pharmaceuticals, and clinical applications. Their specificity and rapid bactericidal action offer distinct advantages over conventional antibiotics, including a potentially lower risk of resistance development. Nonetheless, recent studies report resistance mechanisms such as membrane modifications, efflux pumps, and enzymatic degradation. Despite their potential, only a limited number of bacteriocins have been commercialized primarily for food applications with none yet approved for therapeutic use. Major barriers include low production yields, poor stability, and stringent regulatory challenges. This review presents a comprehensive overview of bacteriocins, including their classification, mechanisms of action, and commercial landscape. It further highlights current innovations aimed at overcoming translational bottlenecks, such as genetic engineering, nanotechnology-based delivery, and fermentation optimization. Ultimately, the review underscores the need for interdisciplinary research and harmonized regulatory frameworks to fully realize bacteriocins' potential in addressing the global antibiotic resistance crisis.

细菌素的商业利用:应对挑战并探索其作为抗生素替代品的潜力。
全球抗生素耐药性的激增加速了对替代抗微生物策略的寻找,细菌素成为有希望的候选药物。这些核糖体合成的肽对多药耐药(MDR)病原体具有有效的靶向抗菌活性,并在食品保存、药物和临床应用中显示出功效。它们的特异性和快速杀菌作用比传统抗生素具有明显的优势,包括潜在的更低的耐药性风险。尽管如此,最近的研究报道了耐药机制,如膜修饰、外排泵和酶降解。尽管它们具有潜力,但只有有限数量的细菌素主要用于食品应用的商业化,尚未批准用于治疗用途。主要障碍包括产量低、稳定性差和严格的监管挑战。本文综述了细菌素的分类、作用机制和商业前景。它进一步强调了当前旨在克服转化瓶颈的创新,如基因工程、基于纳米技术的递送和发酵优化。最后,该综述强调了跨学科研究和协调监管框架的必要性,以充分实现细菌素在解决全球抗生素耐药性危机方面的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Future microbiology
Future microbiology 生物-微生物学
CiteScore
4.90
自引率
3.20%
发文量
134
审稿时长
6-12 weeks
期刊介绍: Future Microbiology delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this increasingly important and vast area of research.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信